A nomogram to predict individual prognosis in node-negative breast carcinoma

European Journal of Cancer

Volumn 48, Issue 16, 2012, Pages 2954-2961

  Mazouni, C ^a,b   Spyratos, F ^c   Romain, S ^a   Fina, F ^a   Bonnier, P ^d   Ouafik, L H ^a   Martin, P M ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c INSTITUT CURIE   (France)

^d Service Urgence SMUR UHCD Centre hospitalier de Montbrison   (France)

Author keywords

Adjuvant!; Breast cancer; Nomogram; PAI 1; Prognosis score

Indexed keywords

ESTROGEN RECEPTOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROGESTERONE RECEPTOR; THYMIDINE KINASE; UROKINASE;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; COMPARATIVE STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; NODE NEGATIVE BREAST CARCINOMA; NOMOGRAM; PREDICTION; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; STATISTICAL MODEL; TUMOR VOLUME;

AGE FACTORS; BREAST NEOPLASMS; CARCINOMA; CHEMOTHERAPY, ADJUVANT; DECISION SUPPORT TECHNIQUES; DISEASE-FREE SURVIVAL; FEMALE; FRANCE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPH NODES; MASTECTOMY, MODIFIED RADICAL; MASTECTOMY, SEGMENTAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NOMOGRAMS; PATIENT SELECTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTORS, PROGESTERONE; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84867571970     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.04.018     Document Type: Article

References (35)

1. N. Harbeck, and C. Thomssen A new look at node-negative breast cancer Oncologist 16 Suppl. 1 2011 51 60
2. D.A. Berry, C. Cirrincione, and I.C. Henderson Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer JAMA 295 2006 1658 1667
3. J.J. Dignam, V. Dukic, and S.J. Anderson Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer Breast Cancer Res Treat 116 2009 595 602
4. A. Goldhirsch, J.N. Ingle, and R.D. Gelber Panel members. Thresholds for therapies: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2009 Ann Oncol 20 2009 1319 1329
5. L. Harris, H. Fritsche, and R. Mennel American Society of Clinical Oncology. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer J Clin Oncol 2007 25 2007 5287 5312
6. C.M. Sturgeon, M.J. Duffy, and U.H. Stenman National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers Clin Chem 54 2008 e11 e79
7. E.J. Kantelhardt, M. Vetter, and M. Schmidt Prospective evaluation of prognostic factors uPA/PAI-1 in node-negative breast cancer: phase III NNBC3-Europe trial [AGO, GBG, EORTC-PBG] comparing 6 × FEC versus 3 × FEC/3 × docetaxel BMC Cancer 11 2011 140
8. F. Descotes, B. Riche, and S. Saez Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator Clin Breast Cancer 8 2008 168 177
9. M. Gnant, N. Harbeck, and C. Thomssen St. Gallen 2011: summary of the consensus discussion Breast Care [Basel] 2011 6 2011 136 141
10. M. Schmidt, A. Victor, and D. Bratzel Long-term outcome prediction by clinicopathological risk classification algorithms in node-negative breast cancer-comparison between Adjuvant!, St. Gallen, and a novel risk algorithm used in the prospective randomized node-negative-breast cancer-3 [NNBC-3] trial Ann Oncol 20 2009 258 264
11. S. Romain, F. Spyratos, and C. Lainé-Bidron Comparative study of four extraction procedures for urokinase type plasminogen activator and plasminogen activator inhibitor-1 in breast cancer tissues Eur J Clin Chem Clin Biochem 33 1995 603 608
12. S. Romain, P.O. Bendahl, and O. Guirou DNA-synthesizing enzymes in breast cancer [thymidine kinase, thymidylate synthase and thymidylate kinase]: association with flow cytometric S-phase fraction and relative prognostic importance in node-negative premenopausal patients Int J Cancer 95 2001 56 61
13. J. Bogaerts, F. Cardoso, and M. Buyse Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial Nat Clin Pract Oncol 3 2006 540 551
14. M.W. Kattan, J.A. Eastham, and A.M. Stapleton A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer J Natl Cancer Inst 90 1998 766 771
15. D.G. Altman, and P. Royston What do we mean by validating a prognostic model? Stat Med 19 2000 453 473
16. F.E. Harrell Regression modeling strategies 2001 Springer New York
17. K.J. Van Zee, D.M. Manasseh, and J.L. Bevilacqua A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy Ann Surg Oncol 10 2003 1140 1151
18. R. Rouzier, L. Pusztai, and S. Delaloge Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer J Clin Oncol 23 2005 8331 8339
19. G. Houvenaeghel, C. Nos, and S. Giard A nomogram predictive of non-sentinel lymph node involvement in breast cancer patients with a sentinel lymph node micrometastasis Eur J Surg Oncol 35 2009 690 695
20. E.O. Hanrahan, A.M. Gonzalez-Angulo, and S.H. Giordano Overall survival and cause-specific mortality of patients with stage T1a, bN0M0 breast carcinoma J Clin Oncol 25 2007 4952 4960
21. C. Mazouni, S. Romain, and P. Bonnier A nomogram predicting the probability of primary breast cancer survival at 2- and 5-years using pathological and biological tumor parameters J Surg Oncol 103 2011 746 750
22. P.M. Ravdin, L.A. Siminoff, and G.J. Davis Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 2001 980 991
23. I.A. Olivotto, C.D. Bajdik, and P.M. Ravdin Population-based validation of the prognostic model ADJUVANT! for early breast cancer J Clin Oncol 23 2005 2716 2725
24. A.J. Vickers Prediction models in cancer care CA Cancer J Clin 2011 10.3322/caac.20118
25. S.F. Shariat, M.W. Kattan, and A.J. Vickers Critical review of prostate cancer predictive tools Future Oncol 5 2009 1555 1584
26. M.A. Rochester, N. Pashayan, and F. Matthews Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population BMC Urol 9 2009 7
27. M. Look, W. van Putten, and M. Duffy Pooled analysis of prognostic impact of uPA and PAI-1 in breast cancer patients Thromb Haemost 90 2003 538 548
28. M. Schmitt, K. Mengele, and R. Napieralski Clinical utility of level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1 Expert Rev Mol Diagn 10 2010 1051 1067
29. K. Malinowsky, C. Böllner, and S. Hipp UPA and PAI-1 analysis from fixed tissues - new perspectives for a known set of predictive markers Curr Med Chem 17 2010 4370 4377
30. S. Haas, T.W. Park, J.C. Hahne, and H.P. Fischer Influence of preoperative core biopsieson uPA/PAI-1 expression in breast cancer tissue Virchows Arch 452 2008 277 283
31. C. Thomssen, N. Harbeck, and J. Dittmer Feasibility of measuring theprognostic factors uPA and PAI-1 in core needle biopsy breast cancer specimens J Natl Cancer Inst 101 2009 1028 1029
32. J.C. Biermann, L. Holzscheiter, and M. Kotzsch Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA Int J Mol Med 21 2008 251 259
33. P.J. Lamy, T. Verjat, and A.C. Servanton Urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 mRNA assessment in breast cancer by means of NASBA: correlation with protein expression Am J Clin Pathol 128 2007 404 413
34. A.D. Hibberd, L.J. Horwood, and J.E. Wells Long term prognosis of women with breast cancer in New Zealand: study of survival to 30 years BMJ 286 1983 1777 1779
35. H. Brenner, and T. Hakulinen Are patients diagnosed with breast cancer before age 50 years ever cured? J Clin Oncol 22 2004 432 438